Latham & Watkins Advises Fractyl Health in its US$100 Million Series F Financing

A Boston-based team advises the company pioneering treatments for metabolic diseases.

June 16, 2021

Fractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, has announced the closing of a US$100 million Series F financing. The financing was led by new investors Maverick Capital, M28 Capital, and Population Health Partners, with participation by other new and existing investors.

Latham & Watkins LLP represents Fractyl Health in the financing with a Boston-based corporate deal team led by partners Hans Brigham, Evan Smith, and Spencer Ricks.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.